UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Apple Turns 50: From Garage Startup to AI Crossroads 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Britain Courts Anthropic Amid US Defense Department Dispute 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
CAMBRIDGE, Mass., Nov. 22, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the 28th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace in New York City, NY on Wednesday, November 30, 2016, at 1:00pm Eastern time.
The presentation will be webcast live and may be accessed from the news and events section of the Vericel website: www.vcel.com/events.
About Vericel Corporation
Vericel develops, manufactures, and markets autologous expanded cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Carticel® (autologous cultured chondrocytes) is an autologous chondrocyte implant for the treatment of cartilage defects in the knee in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is also developing two additional cell products. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous chondrocyte implant intended to treat cartilage defects in the knee. Ixmyelocel T is an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy (DCM). For more information, please visit the company's website at www.vcel.com.
Epicel®, Carticel®, and MACI® are registered trademarks of Vericel Corporation. © Vericel Corporation. All rights reserved.
CONTACT: Chad Rubin The Trout Group [email protected] (646) 378-2947 or Lee Stern The Trout Group [email protected] (646) 378-2922
